论文部分内容阅读
目的分析美罗华联合化疗治疗肠道弥漫大B细胞淋巴瘤的疗效及不良反应。方法对选取的15例肠道弥漫大B细胞淋巴瘤患者采用美罗华联合CTNP方案化疗,每21天为1周期,观察疗效及不良反应。结果15例美罗华联合化疗治疗的患者完全缓解12例,部分缓解2例,死亡1例。结论美罗华联合化疗治疗肠道DLBCL疗效较好,治疗过程中注意不良反应,及时调整剂量。
Objective To analyze the curative effect and adverse reactions of rituximab in combination with chemotherapy for diffuse large intestinal B-cell lymphoma. Methods Fifteen cases of enteric diffuse large B-cell lymphoma were treated with rituximab and CTNP regimen, and every 21 days was one cycle. Efficacy and side effects were observed. Results 15 cases of rituximab combined with chemotherapy in patients with complete remission in 12 cases, partial remission in 2 cases and 1 death. Conclusions Rituximab combined with chemotherapy is effective in treating intestinal DLBCL. Attention should be paid to the adverse reactions during the course of treatment, and the dose should be adjusted in time.